基于基因表达综合数据库芯片挖掘结合网络药理学与分子对接探讨芒果苷治疗口腔黏膜下纤维化的机制研究

doi:10.7518/hxkq.2024.2024050

华西口腔医学杂志 ›› 2024, Vol. 42 ›› Issue (4): 444-451.doi: 10.7518/hxkq.2024.2024050

基于基因表达综合数据库芯片挖掘结合网络药理学与分子对接探讨芒果苷治疗口腔黏膜下纤维化的机制研究

宋子毅¹(), 杨超², 张云龙³, 张柱江³, 任天娇³, 张欣悦⁴, 李雪⁴()

^1.齐齐哈尔医学院口腔医学院，齐齐哈尔 161006
^2.齐齐哈尔医学院医学技术学院，齐齐哈尔 161006
^3.齐齐哈尔医学院公共卫生学院，齐齐哈尔 161006
^4.齐齐哈尔医学院基础医学院，齐齐哈尔 161006

收稿日期:2024-01-31 修回日期:2024-04-25 出版日期:2024-08-01 发布日期:2024-07-17
通讯作者: 李雪 E-mail:m19845895120@163.com;lixue_0720@163.com
作者简介:宋子毅，学士，E-mail：m19845895120@163.com
基金资助:
国家级大学生创新创业训练计划项目(202311230035);黑龙江省自然科学基金项目(LH2021H120);齐齐哈尔市科技计划联合引导项目(LSFGG-2023041);齐齐哈尔医学科学院青年博士项目(QMSI2022B-03)

Mechanism of mangiferin in the treatment of oral submucous fibrosis based on Gene Expression Omnibus database chip mining combined with network pharmacology and molecular docking

Song Ziyi¹(), Yang Chao², Zhang Yunlong³, Zhang Zhujiang³, Ren Tianjiao³, Zhang Xinyue⁴, Li Xue⁴()

^1.School of Stomatology, Qiqihar Medical College, Qiqihar 161006, China
^2.College of Medical Technology, Qiqihar Medical College, Qiqihar 161006, China
^3.School of Public Health, Qiqihar Medical College, Qiqihar 161006, China
^4.School of Basic Medicine, Qiqihar Medical College, Qiqihar 161006, China

Received:2024-01-31 Revised:2024-04-25 Online:2024-08-01 Published:2024-07-17
Contact: Li Xue E-mail:m19845895120@163.com;lixue_0720@163.com
Supported by:
National College Students’ Innovation and Entrepreneurship Training Program(202311230035);Heilongjiang Provincial Natural Science Foundation(LH2021H120);Qiqihar Municipal Science and Technology Bureau Joint Guidance Project(LSFGG-2023041);Doctoral Foundation of Qiqihar Academy of Medical Sciences(QMSI2022B-03)

摘要/Abstract

摘要：

目的基于基因表达综合（GEO）数据库芯片挖掘、网络药理学及分子对接技术探讨芒果苷（MF）治疗口腔黏膜下纤维化（OSF）的核心作用靶标及潜在作用机制。方法基于GEO芯片挖掘OSF的潜在治疗靶点，利用数据库预测MF潜在作用靶标和收集OSF疾病靶标，使用EVenn平台绘制维恩图，STRING数据库绘制蛋白质互作（PPI）网络，DAVID平台进行基因本体论（GO）和京都基因与基因组百科全书（KEGG）富集分析，Cytoscape 3.10.1软件绘制药物—靶标—通路—疾病网络图，AutoDocktools 1.5.6软件进行分子对接分析及可视化。结果从多种数据库挖掘得到MF潜在靶标356个，OSF疾病靶标360个，选取PPI网络中排名前15个关键靶蛋白，GO功能及KEGG通路富集分析结果显示，MF治疗OSF主要涉及高级糖基化终末产物-受体（AGE-RAGE）、表皮生长因子受体（EGFR）等信号通路。分子对接显示，MF与丝氨酸蛋白激酶（AKT1）、肿瘤坏死因子（TNF）等核心靶点有较佳结合活性。结论 MF可能通过多靶点、多途径的方式对OSF发挥治疗作用。

关键词: 口腔黏膜下纤维化, 芒果苷, 基因表达综合数据库, 网络药理学, 分子对接

Abstract:

Objective This study aims to investigate the primary target and potential mechanism of mangiferin (MF) in treating oral submucous fibrosis (OSF) through Gene Expression Omnibus (GEO) database chip mining, network pharmacology, and molecular docking techniques. Methods Potential therapeutic targets for OSF were identified using GEO chip data. The potential targets of MF were predicted, and disease-related targets for OSF were collected from databases. A Venn diagram was created using the EVenn platform to identify overlapping targets. The protein-protein interaction (PPI) network was constructed using the STRING database. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the DAVID platform. Cytoscape 3.10.1 software was used to visualize a drug-target-pathway-disease network, while AutoDocktools 1.5.6 software was employed for molecular docking analysis. Results A total of 356 potential targets for MF and 360 disease-related targets for OSF were obtained from multiple databases. The top 15 key target proteins in the PPI network were selected as significant candidates. GO function and KEGG pathway enrichment analyses revealed that MF treatment primarily involved advanced glycation end products-receptor (AGE-RAGE), epidermal growth factor receptor (EGFR), and other signaling pathways associated with OSF pathogenesis. Molecular docking analysis demonstrated that MF exhibited a strong binding activity toward AKT serine kinase 1 (AKT1), tumor necrosis factor (TNF), and other core targets. Conclusion These findings suggest that MF may exert its therapeutic effects on OSF through a multitarget approach involving various signaling pathways.

Key words: oral submucous fibrosis, mangiferin, Gene Expression Omnibus database, network pharmacology, molecular docking

中图分类号:

R781.5

宋子毅, 杨超, 张云龙, 张柱江, 任天娇, 张欣悦, 李雪. 基于基因表达综合数据库芯片挖掘结合网络药理学与分子对接探讨芒果苷治疗口腔黏膜下纤维化的机制研究[J]. 华西口腔医学杂志, 2024, 42(4): 444-451.

Song Ziyi, Yang Chao, Zhang Yunlong, Zhang Zhujiang, Ren Tianjiao, Zhang Xinyue, Li Xue. Mechanism of mangiferin in the treatment of oral submucous fibrosis based on Gene Expression Omnibus database chip mining combined with network pharmacology and molecular docking[J]. West China Journal of Stomatology, 2024, 42(4): 444-451.

图/表 10

图 1

图 2

图 3

图 4

图 5

表 1

图 6

图 7

图 8

图 9

参考文献 29

1	Gayathri K, Malathi N, Gayathri V, et al. Molecular pathways of oral submucous fibrosis and its progression to malignancy[J]. Arch Oral Biol, 2023, 148: 105644.
2	Liu B, Shen M, Xiong J, et al. Synergistic effects of betel quid chewing, tobacco use (in the form of cigarette smo-king), and alcohol consumption on the risk of malignant transformation of oral submucous fibrosis (OSF): a case-control study in Hunan Province, China[J]. Oral Surg O-ral Med Oral Pathol Oral Radiol, 2015, 120(3): 337-345.
3	Das A, Giri S. A review on role of arecoline and its metabolites in the molecular pathogenesis of oral lesions with an insight into current status of its metabolomics[J]. Prague Med Rep, 2020, 121(4): 209-235.
4	Arakeri G, Rai KK, Hunasgi S, et al. Oral submucous fibrosis: an update on current theories of pathogenesis[J]. J Oral Pathol Med, 2017, 46(6): 406-412.
5	Tom A, Baghirath V, Krishna B, et al. Ultrastructural changes of collagen in different histopathological grades of oral submucous fibrosis[J]. J Pharm Bioallied Sci, 2019, 11(): S309-S313.
6	Shen YW, Shih YH, Fuh LJ, et al. Oral submucous fibrosis: a review on biomarkers, pathogenic mechanisms, and treatments[J]. Int J Mol Sci, 2020, 21(19): 7231.
7	郭锦材, 谢辉. 中医药治疗口腔黏膜下纤维化的临床研究进展[J]. 口腔医学研究, 2019, 35(5): 423-426.
	Guo JC, Xie H. Research progress of traditional chinese medicine in treatment of oral submucous fibrosis[J]. J Oral Sci Res, 2019, 35(5): 423-426.
8	Dutta T, Das T, Gopalakrishnan AV, et al. Mangiferin: the miraculous xanthone with diverse pharmacological properties[J].Naunyn Schmiedebergs Arch Pharmacol, 2023, 396(5): 851-863.
9	Zhang L, Huang C, Fan S. Mangiferin and organ fibrosis: a mini review[J]. Biofactors, 2021, 47(1): 59-68.
10	Zhang L, Liu C, Yin L, et al. Mangiferin relieves CCl4-induced liver fibrosis in mice[J]. Sci Rep, 2023, 13(1): 4172.
11	Chen J, Liu B, Xie X, et al. Comparative molecular analy-sis of oral submucous fibrosis and other organ fibrosis ba-sed on weighted gene co-expression network analysis[J]. J Cent South Univ (Med Sci), 2022, 47(12): 1663-1672.
12	Wang X, Wang ZY, Zheng JH, et al. TCM network pharmacology: a new trend towards combining computatio-nal, experimental and clinical approaches[J]. Chin J Nat Med, 2021, 19(1): 1-11.
13	Dong Y, Zhao Q, Wang Y. Network pharmacology-based investigation of potential targets of astragalus membranaceous-angelica sinensis compound acting on diabetic nephropathy[J]. Sci Rep, 2021, 11(1): 19496.
14	Wang N, Li Q. Simultaneous extraction and analysis of seven major saikosaponins from bupleuri radix and the exploration of antioxidant activity and its mechanism[J]. Molecules, 2023, 28(15): 5872.
15	Song J, Meng Y, Wang M, et al. Mangiferin activates Nrf2 to attenuate cardiac fibrosis via redistributing glutaminolysis-derived glutamate[J]. Pharmacol Res, 2020, 157: 104845.
16	Song Y, Liu W, Tang K, et al. Mangiferin alleviates renal interstitial fibrosis in streptozotocin-induced diabetic mice through regulating the PTEN/PI3K/Akt signaling pathway[J]. J Diabetes Res, 2020, 2020: 9481720.
17	Lan A, Du J. Potential role of Akt signaling in chronic kidney disease[J]. Nephrol Dial Transplant, 2015, 30(3): 385-394.
18	Lin Y, Jiang Y, Xian H, et al. Expression and correlation of the Pi3k/Akt pathway and VEGF in oral submucous fibrosis[J]. Cell Prolif, 2023, 56(11): e13491.
19	Siegmund D, Wajant H. TNF and TNF receptors as the-rapeutic targets for rheumatic diseases and beyond[J]. Nat Rev Rheumatol, 2023, 19(9): 576-591
20	Gupta S, Nigam K, Srivastav RK, et al. Genetic polymorphism of tumor necrosis factor alpha (TNF-α) and tumor necrosis factor beta (TNF-β) genes and risk of oral pre-cancer and cancer in North Indian population[J]. Oral Maxillofac Surg, 2022, 26(1): 33-43.
21	Guo ZX, Zhang Z, Yan JF, et al. A biomaterial-based therapy using a sodium hyaluronate/bioglass composite hydrogel for the treatment of oral submucous fibrosis[J]. Acta Biomater, 2023, 157: 639-654.
22	Wu L, Cheng Y, Geng D, et al. O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling[J]. Proc Natl Acad Sci U S A, 2022, 119(10): e2107453119.
23	郭锦材, 谢辉, 吴昊, 等. 姜黄素治疗口腔黏膜下纤维性变有效性的Meta分析[J]. 华西口腔医学杂志, 2021, 39(2): 195-202.
	Guo JC, Xie H, Wu H, et al. Efficacy of curcumin in the treatment of oral submucous fibrosis: a Meta-analysis[J]. West China J Stomatol, 2021, 39 (2): 195-202.
24	Parwani K, Patel F, Bhagwat P, et al. Swertiamarin mitigates nephropathy in high-fat diet/streptozotocin-induced diabetic rats by inhibiting the formation of advanced glycation end products[J]. Arch Physiol Biochem, 2024, 130(2): 136-154.
25	Chang MC, Chan CP, Chen YJ, et al. Areca nut components stimulate ADAM17, IL-1α, PGE2 and 8-isoprostane production in oral keratinocyte: role of reactive oxygen species, EGF and JAK signaling[J]. Oncotarget, 2016, 7(13): 16879-16894.
26	Zhou S, Zhu Y, He Z, et al. Long non-coding RNA expression profile associated with malignant progression of oral submucous fibrosis[J]. J Oncol, 2019, 2019: 6835176.
27	Ho YC, Yang SF, Lee SS, et al. Regulation of hypoxia-inducible factor-1α in human buccal mucosal fibroblasts stimulated with arecoline[J]. J Formos Med Assoc, 2017, 116(6): 484-487.
28	Tsai CH, Lee SS, Chang YC. Hypoxic regulation of plasminogen activator inhibitor-1 expression in human buccal mucosa fibroblasts stimulated with arecoline[J]. J O-ral Pathol Med, 2015, 44(9): 669-673.
29	Fu TL, Li GR, Li DH, et al. Mangiferin alleviates diabetic pulmonary fibrosis in mice via inhibiting endothelial-mesenchymal transition through AMPK/FoxO3/SIRT3 axis[J]. Acta Pharmacol Sin, 2024, 45(5): 1002-1018.

序号	蛋白名称	度值	接近中心性	中介中心性
1	AKT1	20	0.71	0.21
2	TNF	20	0.70	0.19
3	EGFR	16	0.66	0.09
4	SRC	16	0.65	0.08
5	BCL2	15	0.62	0.05
6	MMP9	14	0.60	0.03
7	HIF1A	13	0.59	0.09
8	PTGS2	12	0.58	0.02
9	IGF1	12	0.58	0.03
10	MMP2	11	0.58	0.02
11	ALB	9	0.55	0.04
12	ITGB1	9	0.55	0.09
13	AR	8	0.52	0.03
14	PGR	8	0.51	0.03
15	MAPK8	7	0.52	0.00

[1]	孙金梦, 张颖, 郑泽君, 丁晓玲, 孙敏敏, 丁刚. 基于网络药理学和分子对接技术探讨人参对牙周炎的潜在治疗机制[J]. 华西口腔医学杂志, 2024, 42(2): 181-191.
[2]	杨靖梅, 周子亮, 吴亚菲, 聂敏. 基于网络药理学和分子对接技术探究姜黄素治疗牙周炎的作用机制[J]. 华西口腔医学杂志, 2023, 41(2): 157-164.
[3]	曾小丽, 李生娇, 单铮男, 殷俊豪, 姜吉蕊, 郑章龙, 李家. 基于基因芯片整合分析筛选慢性牙周炎相关基因和转录因子[J]. 华西口腔医学杂志, 2021, 39(6): 633-641.
[4]	杨博,符梦凡,唐瞻贵. 槟榔碱及机械刺激构建大鼠口腔黏膜下纤维化模型[J]. 华西口腔医学杂志, 2019, 37(3): 260-264.
[5]	李宁翦新春许春娇. 兜甲蛋白和细胞色素P4503A5在口腔黏膜下纤维化中的表达及意义[J]. 华西口腔医学杂志, 2009, 27(01): 29-33.

基于基因表达综合数据库芯片挖掘结合网络药理学与分子对接探讨芒果苷治疗口腔黏膜下纤维化的机制研究

Mechanism of mangiferin in the treatment of oral submucous fibrosis based on Gene Expression Omnibus database chip mining combined with network pharmacology and molecular docking

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 10

参考文献 29

相关文章 5

编辑推荐

Metrics

本文评价